ADVFN Logo
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

REUN Reunion Neuroscience Inc

1.12
0.00 (0.00%)
Last Updated: 19:00:00
Delayed by 15 minutes

Period:

Draw Mode:

Volume 0
Bid Price 1.18
Ask Price 1.07
News -
Day High

Low
0.6303

52 Week Range

High
1.45

Day Low
Company Name Stock Ticker Symbol Market Type
Reunion Neuroscience Inc REUN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.00% 1.12 19:00:00
Open Price Low Price High Price Close Price Prev Close
1.12
Trades Volume Avg Volume 52 Week Range
0 0 - 0.6303 - 1.45
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 1.12 USD

Reunion Neuroscience Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 13.12M - - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Reunion Neuroscience News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No REUN Message Board. Create One! See More Posts on REUN Message Board See More Message Board Posts

Historical REUN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.00%
1 Month0.000.000.000.0000.000.00%
3 Months0.000.000.000.0000.000.00%
6 Months0.000.000.000.0000.000.00%
1 Year1.051.450.63031.08255,2040.076.67%
3 Years3.797.620.63031.37142,460-2.67-70.45%
5 Years3.797.620.63031.37142,460-2.67-70.45%

Reunion Neuroscience Description

Reunion Neuroscience Inc. is engaged in the psychedelic drug development company that provides therapeutic solutions for mental health conditions by developing serotonin receptor agonist compounds. The Company is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company¿s products include RE104 and RE200. The Company¿s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The Company is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The Company is focused on the research and development of its RE200 molecule group.

Your Recent History

Delayed Upgrade Clock